Cox regression analysis of treatment-free survival of male B-CLL patients
. | Univariate . | . | Multivariate . | . | ||
|---|---|---|---|---|---|---|
| Parameter . | Relative risk ratio (95% CI) . | P . | Relative risk ratio (95% CI) . | P . | ||
| CD38+ B-CLL cells 30% or greater | 6.6 (3.0-14.4) | < .001 | 6.1 (1.6-23.8) | .009 | ||
| CD38+ T cells 50% or greater | 3.1 (1.6-5.9) | < .001 | 4.0 (1.3-12.5) | .01 | ||
| Ig VH mutational status | 3.1 (1.3-7.2) | < .001 | 3.3 (.96-11.3) | .05 | ||
| High-risk genomic aberrations, 11q-, 17p-, 12+ | 3.0 (1.5-6.1) | .003 | .5 (.15-1.7) | .28 | ||
| Zap-70+ B-CLL cells 20% or greater | 1.8 (1.0-3.4) | .05 | 1.1 (.42-3.3) | .76 | ||
| Rai stage | ||||||
| Intermediate, 1-2 | 9.0 (1.2-67.4) | .03 | 1.8 (2.1-15.1) | .59 | ||
| High, 3-4 | 24.1 (3.2-181.5) | .002 | 1.7 (.18-16.7) | .63 | ||
. | Univariate . | . | Multivariate . | . | ||
|---|---|---|---|---|---|---|
| Parameter . | Relative risk ratio (95% CI) . | P . | Relative risk ratio (95% CI) . | P . | ||
| CD38+ B-CLL cells 30% or greater | 6.6 (3.0-14.4) | < .001 | 6.1 (1.6-23.8) | .009 | ||
| CD38+ T cells 50% or greater | 3.1 (1.6-5.9) | < .001 | 4.0 (1.3-12.5) | .01 | ||
| Ig VH mutational status | 3.1 (1.3-7.2) | < .001 | 3.3 (.96-11.3) | .05 | ||
| High-risk genomic aberrations, 11q-, 17p-, 12+ | 3.0 (1.5-6.1) | .003 | .5 (.15-1.7) | .28 | ||
| Zap-70+ B-CLL cells 20% or greater | 1.8 (1.0-3.4) | .05 | 1.1 (.42-3.3) | .76 | ||
| Rai stage | ||||||
| Intermediate, 1-2 | 9.0 (1.2-67.4) | .03 | 1.8 (2.1-15.1) | .59 | ||
| High, 3-4 | 24.1 (3.2-181.5) | .002 | 1.7 (.18-16.7) | .63 | ||
The analysis included 75 male patients (for whom all risk parameters including high-risk genomic aberrations and Ig VH mutational status were available). The median follow-up for this cohort was 59 months (range, 2-327 months).